NSF award 2538091 · Endure Biotherapeutics, INC.
SBIR Phase I: A Novel Precision Microbiome Therapy for Phenylketonuria
Final report due
30 April 2027
in 194 days · The award ends on 31 December 2026.
GrantClerk is a private service. We are not NSF or any government agency.
Dates this award owes
NSF emails you about this too.
- Extension request16 Nov 2026in 29 days
award ending 2026-12-31 · Research.gov
- No-cost extension notice21 Dec 2026in 64 days
award ending 2026-12-31 · Research.gov
- Final report due30 Apr 2027in 194 days
award ending 2026-12-31 · Research.gov
- Project outcomes report due30 Apr 2027in 194 days
award ending 2026-12-31 · Research.gov
- Award is closed out30 Apr 2027in 194 days
award ending 2026-12-31 · Research.gov
Annual report dates come from the budget period on your award notice. That date is not public, so it is not shown here.
How we got this date
- NSF lists this award's end date as 31 December 2026.
- NSF rules say the final report is due no later than 120 days after that.
- So the final report is due by 30 April 2027.
Get a note before each report date
Add this award to your desk. We email you before each date and keep the dates in one place.
Renews each year until you cancel. Cancel any time from your account.
Award card
- Award number
- 2538091
- Period of support
- 1 Jul 2026 – 31 Dec 2026
- Amount
- $305,000
- Awardee
- Endure Biotherapeutics, INC., Carlsbad, CA
- Program
- SBIR Phase I
- Directorate
- TIP
Abstract
The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project proposed by the small business will develop the proprietary, precision microbiome-based therapeutic platform for Phenylketonuria (PKU) incorporating engineered native bacteria. PKU is a rare inherited metabolic disorder caused by a deficiency of the enzyme phenylalanine hydroxylase, resulting in toxic…
Is this right?
We copy this from the public NSF award record. Your award notice and NSF always win. If a date looks wrong, check Research.gov.